BREAKING NEWS

Medicare will limit coverage of a controversial Alzheimer's drug to patients in clinical trials, citing concerns about safety and efficacy.

Thursday, April 7, 2022 4:45 PM EST

Advocacy groups for patients have said the federal insurance program for people 65 and over must pay for a drug approved by the Food and Drug Administration. Many Alzheimer's doctors and experts cautioned against broadly covering a treatment that scientific evidence shows has uncertain benefit and serious safety risks.

Read the latest